Contact information
https://orcid.org/0000-0002-1256-874X
Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, OXFORD. OX3 7LJ
Rury Holman
MB, ChB. FRCP(Lon). FMedSci
Emeritus Professor of Diabetic Medicine
- Emeritus Diabetes Trials Unit Director
- Emeritus NIHR Senior Investigator
Rury Holman trained in medicine at the University of Bristol and was appointed Honorary Consultant Physician to the University of Oxford NHS Hospitals Trust in 1985, at which time he founded the University of Oxford Diabetes Trials Unit. He was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998 and as the founding Academic Chairman of the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) in 2003. He is a Fellow of the Academy of Medical Sciences, an Emeritus NIHR Senior Investigator and Emeritus Professor of Diabetic Medicine. Professor Holman has won many distinguished international awards including the ADA Harold Rifkin Award for Distinguished International Service, the ADA Outstanding Achievement in Clinical Diabetes Research Award, the Diabetes UK Banting Memorial Lecture, the Diabetes UK Robert Turner Award for Research Impact and the ADA Banting Medal for Scientific Achievement Award.
Recent publications
α-Hydroxybutyrate and Cardiovascular Outcomes in People Living With Type 2 Diabetes: An EXSCEL Post Hoc Analysis.
Journal article
Noormandi A. et al, (2026), Diabetes Obes Metab
Serial assessment of NT-proBNP and high-sensitivity cardiac troponin with glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes: Insights from EXSCEL.
Journal article
Kittipibul V. et al, (2026), Am Heart J, 299
A validated, modifiable proteomic score from the EXSCEL trial predicts cardiovascular events in diabetes.
Journal article
Corey KM. et al, (2026), JCI Insight, 11
Semaglutide treatment fails but might prevent Alzheimer's disease.
Journal article
Koychev I. and Holman RR., (2026), Lancet, 408, 602 - 603
To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial.
Journal article
Güdemann LM. et al, (2026), Diabetes Care, 49, 1458 - 1466